@article{Khristianovsky_Belimenko_2021, title={Technology for the Use of Reduced Doses of Diminazene Aceturate for the Treatment of Pet Babesiosis}, volume={6}, url={https://knepublishing.com/index.php/KnE-Life/article/view/8953}, DOI={10.18502/kls.v0i0.8953}, abstractNote={<p>Babesiosis (piroplasmosis) is a transmissible parasitic disease, accompanied by fever, anemia, yellowness of the mucous membranes, hemoglobinuria, lost productivity and performance, and with untimely treatment – death of livestock. Therapy to treat livestock babesiosis involves, first of all, the use of anti-babesial drugs. This study aimed the examine the effectiveness of using a reduced diminazene aceturate (DA) dosage against babesiosis in livestock. However, the use of these drugs can cause side effects. The study recommends the use of DA-based drugs against equine babesiosis at a dose of 2.6 mg/kg bodyweight for an active ingredient (AI). With volumetric dosing it is 0.038 cm3 of a 7 % solution per kg bodyweight, rather than 0.05 cm3 per kg bodyweight, as indicated in the instructions. The use of a reduced dose of Batrizin (2.5 and 3.0 mg/kg AI) and Fa.Try.Banil. (2.5 mg/kg AI) to treat experimental babesiosis in dogs had a satisfactory anti-babesial effect in the absence of intoxication.</p> <p><strong>Keywords</strong>: diminazene aceturate, babesiosis, parasitic disease</p&gt;}, number={3}, journal={KnE Life Sciences}, author={Khristianovsky , Pavel and Belimenko, Vladislav}, year={2021}, month={Apr.}, pages={240–246} }